metformin vitabalans 500 mg apvalkotās tabletes
vitabalans oy, finland - metformīna hidrohlorīds - apvalkotā tablete - 500 mg
metformin vitabalans 1000 mg apvalkotās tabletes
vitabalans oy, finland - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg
vilspox 50 mg/850 mg apvalkotās tabletes
sandoz d.d., slovenia - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
metformin teva 1000 mg apvalkotās tabletes
teva pharma b.v., netherlands - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg
daltex 50 mg/850 mg apvalkotās tabletes
medochemie ltd., cyprus - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
daltex 50 mg/1000 mg apvalkotās tabletes
medochemie ltd., cyprus - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
metfogamma 850 mg apvalkotās tabletes
wörwag pharma gmbh & co.kg, germany - metformīna hidrohlorīds - apvalkotā tablete - 850 mg
vilspox 50 mg/1000 mg apvalkotās tabletes
sandoz d.d., slovenia - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
metfogamma 500 mg apvalkotās tabletes
wörwag pharma gmbh & co.kg, germany - metformīna hidrohlorīds - apvalkotā tablete - 500 mg
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastiski līdzekļi - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.